URL has been copied successfully!
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Oppenheimer analyst Matthew Biegler initiated coverage on Aprea Therapeutics Inc (NASDAQ:APRE) with an Outperform rating and announced a price target of $5. Aprea Therapeutics shares closed at $0.83 on Wednesday. See how other analysts view this stock.
- Northland Capital Markets analyst …
Please follow us:
This post was originally published here
